Analysis of the application value of sequential nasal high flow ventilation for blood gas indexes in patients with severe respiratory failure
Objective To study and analyze the application value of sequential nasal high flow ventilation therapy on blood gas indexes in patients with severe respiratory failure. Methods A total of 60 patients with severe respiratory failure admitted from March 2021 to March 2022 were randomly divided into study group and control group to receive sequential nasal high-flow ventilation therapy and non-invasive mechanical ventilation therapy, respectively. The treatment of the two groups was compared. Results PaCO2 was (39.63±2.62) mmHg, PaO2 was (67.32±3.45) mmHg, SpO2 was (96.63±1.62) ％, PaCO2/FiO2 was (181.32±18.45), and the total ventilation time was (3.08±1.65) d. The number of intervention was (9.63±3.62) times, the cost was (1415.31±6.25) yuan, the length of hospitalization was (4.32±8.45) d, the incidence of complications was 10.00％, and the rate of re-intubation was 6.67％. In control group, after treatment, PaCO2 was (45.45±2.52) mmHg, PaO2 was (60.62±3.52) mmHg, SpO2 was (94.45±1.52) ％, PaCO2/FiO2 was (174.62±17.52) d, and total ventilation time was (6.39±1.62) d. The number of intervention was (18.45±3.52) times, the cost was (2 116.04±6.37) yuan, the length of hospitalization was (7.62±7.52) d, the incidence of complications was 30.00％, and the rate of re-intubation was 33.33％. All indexes in the study group were significantly better than those in the control group, and the difference between groups was statistically significant (P＜0.05). Conclusion The clinical effect of sequential nasal high-flow ventilation therapy is more significant in patients with severe respiratory failure, which can ensure more stable blood gas indexes and high treatment safety, and patients do not need to endure the pain of re-intubation.
sequential nasal high-flow ventilation therapysevere respiratory failureblood gas indexapplication value
万方数据
